Calcium in the coronary arteries is a known cardiac risk factor. However, new data suggest it may actually tell us more about a person's overall health than researchers previously believed.
Researchers warned that “aggressive procedural modifications” should not be necessary during TAVR to mitigate the risk of prosthesis-patient mismatch. This appears to be true for patients receiving both self-expanding and balloon-expandable TAVR valves.
Ramon Varcoe, MBBS, co-principal investigator for the LIFE-BTK trial, discussed the results with Cardiovascular Business at TCT 2023. "I can't wait to start using these in my patients. It's going to make a huge difference."
Firas Zahr, MD, spoke to Cardiovascular Business about early data on the Medtronic TMVR device. His team's study is designed to follow patients for a total of five years.
There were some concerns among researchers after one study suggested iFR may increase the risk of mortality. New data presented at TCT 2023, however, showed that the two technologies are linked to similar outcomes.